Complete
Acquisition du traitement CAR-T Kymriah (tisagenlecleucel)
✨
Quick Summary
This opportunity involves the acquisition of the CAR-T therapy Kymriah (tisagenlecleucel) in Quebec. It is related to specialized medical treatment procurement.
Ideal For
Pharmaceutical companies or authorized distributors specializing in advanced cancer therapies should bid.
medical suppliespharmaceuticalsbiotechnologyhealthcarecancer treatment
High complexityTender Details
- Reference Number
- ocds-ec9k95-20050540
- Publication Date
- Feb 21, 2025